Burning Rock Biotech Ltd BNR
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $77.2M | $70.7M | $75.7M | $81.7M | $79.7M | $65.9M | — |
| Cost of revenue | $19.5M | $21.0M | $24.5M | $26.6M | $22.6M | $17.8M | — |
| Gross profit | $57.6M | $49.6M | $51.2M | $55.1M | $57.1M | $48.1M | — |
| R&D | $23.8M | $31.8M | $48.9M | $61.2M | $57.7M | $40.5M | — |
| SG&A | $18.0M | $35.8M | $61.7M | $82.4M | $76.9M | $45.0M | — |
| Operating income | -$7.8M | -$49.0M | -$94.3M | -$142.1M | -$125.1M | -$63.2M | — |
| Interest expense | $4.0K | $0 | $0 | $15.0K | $241.0K | $102.0K | — |
| Pre-tax income | -$7.7M | -$46.7M | -$91.7M | -$140.5M | -$124.9M | -$62.4M | — |
| Income tax | $223.0K | $806.0K | $336.0K | $288.0K | $141.0K | $0 | — |
| Net income | -$7.9M | -$47.5M | -$92.1M | -$140.8M | -$125.0M | -$62.4M | — |
| EPS, diluted | — | — | — | — | 0.00 | 0.00 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $68.4M | $74.7M | $84.3M | $130.3M | $208.7M | $302.1M | $15.1M |
| Short-term investments | — | — | — | $0 | $10.0M | $55.5M | — |
| Receivables | $24.3M | $20.8M | $17.9M | $15.9M | $14.5M | $13.5M | — |
| Inventory | $6.9M | $8.6M | $9.7M | $18.9M | $19.3M | $10.4M | — |
| Total current assets | $105.6M | $106.4M | $124.5M | $182.5M | $285.7M | $386.8M | — |
| Property, plant and equipment | $4.4M | $6.5M | $18.6M | $36.5M | $51.1M | $17.1M | — |
| Other intangibles | $41.0K | $58.0K | $136.0K | $288.0K | $808.0K | $530.0K | — |
| Total assets | $117.3M | $121.3M | $146.5M | $230.2M | $357.6M | $408.1M | — |
| Accounts payable | $5.8M | $4.6M | $2.5M | $7.4M | $9.9M | $5.4M | — |
| Short-term debt | — | — | — | $0 | $372.0K | $1.1M | — |
| Total current liabilities | $35.3M | $36.5M | $37.1M | $59.7M | $58.4M | $37.0M | — |
| Total liabilities | $40.8M | $41.7M | $38.3M | $62.2M | $68.0M | $37.1M | — |
| Retained earnings | -$608.5M | -$575.4M | -$542.8M | -$463.9M | -$349.7M | -$217.3M | — |
| Total equity | $76.5M | $79.6M | $108.2M | $167.9M | $289.6M | $371.0M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.1M | -$12.6M | -$36.0M | -$66.2M | -$75.0M | -$11.3M | — |
| Depreciation and amortisation | $3.1M | $7.2M | $18.8M | $18.0M | $7.5M | $5.1M | — |
| Stock-based compensation | $2.0M | $21.3M | $36.7M | $47.4M | $44.3M | $26.5M | — |
| Capital expenditure | $751.0K | $742.0K | $1.1M | $9.0M | $32.1M | $9.2M | — |
| Investing cash flow | -$628.0K | -$604.0K | -$1.3M | -$1.1M | $12.8M | -$16.8M | — |
| Financing cash flow | $272.0K | -$10.0K | -$6.9M | -$12.5M | -$8.3M | $331.9M | — |
| Buybacks | — | — | — | — | $0 | $0 | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-183377.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $65.9M | $79.7M | $81.7M | $75.7M | $70.7M | $77.2M |
| Gross profit | — | $48.1M | $57.1M | $55.1M | $51.2M | $49.6M | $57.6M |
| Net income | — | -$62.4M | -$125.0M | -$140.8M | -$92.1M | -$47.5M | -$7.9M |
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $58.23B | — | 35.9% |
| DGX | QUEST DIAGNOSTICS INC | $26.70B | 27.6x | 11.8% |
| LH | LABCORP HOLDINGS INC. | $26.68B | 31.4x | 7.2% |
| GH | Guardant Health, Inc. | $22.69B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $9.04B | — | 97.0% |
| GRAL | GRAIL, Inc. | $5.92B | — | 17.2% |
| RDNT | RadNet, Inc. | $5.54B | — | 11.5% |
| BLLN | BillionToOne, Inc. | $5.00B | 769.8x | 100.0% |